Security Snapshot

ArriVent BioPharma, Inc. - COMMON STOCK (AVBP) Institutional Ownership

CUSIP: 04272N102

13F Institutional Holders and Ownership History from Q1 2024 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

110

Shares (Excl. Options)

40.82MFull value: 40,823,807 · shares · 30 Sep 2026

Price

$30.28

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+3,644,993
Value change
+$108,950,995
Number of holders
110
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
49,367,935
SEC-reported price per share
$21.00
Insider filing price
$21.00
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • AVBP - ArriVent BioPharma, Inc. - COMMON STOCK is tracked under CUSIP 04272N102.
  • 110 institutions reported positions in Q3 2026.
  • 11 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 156 to 110 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $1.6BFull value: $1,601,712,202 · USD · 30 Jun 2026
    to
    $1.24BFull value: $1,236,139,622 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 110 institutions filings for Q3 2026.

Open SEC evidence

Security key

04272N102

13F reference period

Q3 2026

13F holders

110

13D/G owners

11

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
11
Security
AVBP
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
INFINITUM ASSET MANAGEMENT, LLC 9.9% 0% $90,602,588 +$15,488,850 4,123,923 +21% INFINITUM ASSET MANAGEMENT, LLC 31 Dec 2025
HILLHOUSE INVESTMENT MANAGEMENT, LTD. 9.5% $86,322,700 3,929,117 Hillhouse Investment Management, Ltd. 31 Dec 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 9.9% $75,183,720 3,412,788 Suvretta Capital Management, LLC 30 Jun 2025
BlackRock, Inc. 6.8% +20% $110,545,459 +$29,971,553 3,182,080 +37% BlackRock, Inc. 30 Jun 2026
ORBIMED ADVISORS LLC 5.8% -21% $87,081,253 -$4,583,211 2,875,962 -5% ORBIMED ADVISORS LLC 06 Oct 2026
FMR LLC 5.8% -14% $47,130,580 -$2,514,956 2,863,340 -5.1% FMR LLC 30 Sep 2026
Vivo Opportunity Fund Holdings, L.P. 5% $74,872,644 2,472,701 Vivo Opportunity, LLC 06 Oct 2026
HBM Healthcare Investments (Cayman) Ltd. 5.4% $40,491,643 2,195,014 HBM Healthcare Investments (Cayman) Ltd. 08 Oct 2025
Octagon Capital Advisors LP 4.9% $36,365,946 1,971,054 Octagon Capital Advisors LP 30 Sep 2025
VANGUARD GROUP INC 4.5% -9.6% $37,611,688 -$3,224,708 1,869,266 -7.9% The Vanguard Group 31 Dec 2025
Sofinnova Venture Partners IX, L.P. 4.1% $35,767,532 1,696,752 Sofinnova Venture Partners XI, L.P. ("SVP XI") 31 Dec 2025
As of 30 Sep 2026, 110 institutional investors reported holding
40.82MFull value: 40,823,807 · shares · 30 Sep 2026
shares of ArriVent BioPharma, Inc. - COMMON STOCK (AVBP). This represents 83% of the company’s total
49.37MFull value: 49,367,935 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
65%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MONTANOVA CAPITAL, LLC 10% 4,925,531 4.1% $149,145,079
INFINITUM ASSET MANAGEMENT, LLC 9.2% 4,523,923 12% $136,984,388
ORBIMED ADVISORS LLC 6.1% 3,027,328 1.7% $91,667,492
Octagon Capital Advisors LP 4.3% 2,141,387 8.8% $64,841,198
VANGUARD CAPITAL MANAGEMENT LLC 4.1% 2,011,253 0% $60,900,741
Vivo Capital, LLC 3.6% 1,787,104 6% $54,113,509
STATE STREET CORP 3.6% 1,763,099 0% $53,386,638
Sofinnova Investments, Inc. 3.4% 1,696,752 2.5% $51,377,651
Logos Global Management LP 2.7% 1,350,000 2.4% $40,878,000
NOVO HOLDINGS A/S 2.4% 1,175,000 2.4% $35,579,000
GOLDMAN SACHS GROUP INC 2.2% 1,107,094 0% $33,522,807
BANK OF AMERICA CORP /DE/ 2.2% 1,070,867 0% $32,425,853
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,055,218 0% $31,958,887
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.4% 685,526 0.03% $20,757,727
HSG Holding Ltd 1.3% 663,308 1.6% $20,084,966
Point72 Asset Management, L.P. 1% 493,205 0.02% $14,934,247
Foresite Capital Management VI LLC 0.99% 490,341 2.6% $14,847,525
Seven Fleet Capital Management LP 0.91% 451,173 2.7% $13,661,518
VANGUARD PORTFOLIO MANAGEMENT LLC 0.79% 389,831 0% $11,804,083
DIMENSIONAL FUND ADVISORS LP 0.66% 324,998 0% $9,838,127
VANGUARD FIDUCIARY TRUST CO 0.6% 296,350 0% $8,973,478
E Fund Management Co., Ltd. 0.56% 277,804 0.19% $8,411,905
ACUTA CAPITAL PARTNERS, LLC 0.35% 170,893 4% $5,174,640
Woodline Partners LP 0.31% 153,329 0.01% $4,642,802
WELLINGTON MANAGEMENT GROUP LLP 0.27% 133,821 0% $4,052,101

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
11
Headline period
Q3 2026
Rows shown
1-11 of 11
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 40,823,807 $1,236,139,622 +$108,950,995 $30.28 110
2026 Q2 46,122,258 $1,601,712,202 +$151,186,563 $34.74 156
2026 Q1 42,089,344 $969,468,905 +$42,325,450 $23.07 138
2025 Q4 40,108,234 $810,286,038 +$21,067,734 $20.12 122
2025 Q3 38,570,342 $712,380,900 +$89,390,684 $18.45 104
2025 Q2 33,625,800 $732,036,140 +$99,572,817 $21.77 96
2025 Q1 29,075,127 $539,323,391 +$6,162,682 $18.49 82
2024 Q4 28,465,885 $757,455,987 +$26,598,551 $26.64 80
2024 Q3 25,909,614 $612,333,484 +$70,385,573 $23.50 68
2024 Q2 20,990,668 $389,375,916 -$3,300,286 $18.55 53
2024 Q1 21,851,940 $388,890,872 +$388,416,714 $17.86 53
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .